Case Reports Open access

Autologous hematopoietic stem-cell transplantation in diffuse cutaneous systemic sclerosis: a single-center experience

Authors

Published
28 May 2025
Section
Case Reports

Abstract

Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by multisystem involvement. Patients can be stratified into an indolent or rapidly progressive disease course. A progressive course warrants early and more aggressive treatment to prevent irreversible organ damage. Therapeutic strategies should be tailored to the presenting symptoms and organ involvement. Autologous hematopoietic stem cell transplantation (AHSCT) has proven to be an effective treatment modality for specific phenotypes of SSc, especially progressive diffuse cutaneous SSc. However, the optimal timing for the transplantation remains unknown. We present two cases of rapidly progressive diffuse cutaneous SSc (dcSSc) treated with AHSCT following inadequate response to conventional immunosuppressive therapy. While both patients experienced significant cutaneous improvement post-AHSCT, internal organ involvement progressed in one case, ultimately resulting in a fatal outcome due to severe sepsis, whereas the second patient remained clinically stable and without immunosuppressive therapy during long-term follow-up. This report contributes to the growing body of evidence supporting AHSCT as a therapeutic option in carefully selected cases of progressive dcSSc. To our knowledge, our cases are the first successful experiences with this treatment modality in Croatia and among the Slavic populations of the Balkan Peninsula, promoting the need for earlier interventions in patients who develop a progressive disease course, particularly with skin involvement.

Ethics Approval

The study was approved by the Ethics committee of University Hospital Centre Zagreb (approval number: 8.1-23/249-2; 02/013 AG).

References

  1. Denton CP. Advances in pathogenesis and treatment of systemic sclerosis. Clin Med 2016; 16: 55-60. DOI: https://doi.org/10.7861/clinmedicine.16-1-55
  2. Denton CP, Khanna D. Systemic sclerosis. Lancet 2017; 390: 1685-99. DOI: https://doi.org/10.1016/S0140-6736(17)30933-9
  3. Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, et al. Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheumatol 2017; 69: 1067-77. DOI: https://doi.org/10.1002/art.40027
  4. Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76: 1897-905. DOI: https://doi.org/10.1136/annrheumdis-2017-211448
  5. Cen X, Feng S, Wei S, Yan L, Sun L. Systemic sclerosis and risk of cardiovascular disease: a PRISMA-compliant systemic review and meta-analysis of cohort studies. Medicine 2020; 99: e23009. DOI: https://doi.org/10.1097/MD.0000000000023009
  6. Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, Čolić J, Santiago T, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 2025; 84: 29-40. DOI: https://doi.org/10.1136/ard-2024-226430
  7. Higashitani K, Takase-Minegishi K, Yoshimi R, Kirino Y, Hamada N, Nagai H, et al. Benefits and risks of haematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis. Mod Rheumatol 2023; 33: 330-7. DOI: https://doi.org/10.1093/mr/roac026
  8. Schmalzing M, Henes J, Van Laar JM, Sullivan KM. Editorial: Stem cell transplantation in autoimmune diseases (AID). Front Immunol. 2023;14:1150664. DOI: https://doi.org/10.3389/fimmu.2023.1150664
  9. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15. DOI: https://doi.org/10.1136/ard.2009.114264
  10. Jones XM, Bottini N, Boin F, Marbán E. Cardiac involvement in systemic sclerosis: A critical review of knowledge gaps and opportunities. J Scleroderma Relat Disord 2025: 23971983241313096. DOI: https://doi.org/10.1177/23971983241313096
  11. Giucă A, Gegenava T, Mihai CM, Jurcuţ C, Săftoiu A, Gȋrniţă DM, et al. Sclerodermic cardiomyopathy-a state-of-the-art review. Diagnostics 2022; 12: 669. DOI: https://doi.org/10.3390/diagnostics12030669
  12. Fairley JL, O’Rourke R, Puranik R, Nikpour M. Cardiac magnetic resonance imaging in systemic sclerosis: Heart involvement in high-resolution. Rheumatol Immunol Res 2024; 5: 83-92. DOI: https://doi.org/10.1515/rir-2024-0011
  13. Del Papa N, Onida F, Zaccara E, Saporiti G, Maglione W, Tagliaferri E, et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant 2017; 52: 53-8. DOI: https://doi.org/10.1038/bmt.2016.211
  14. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 2018; 378: 35-47. DOI: https://doi.org/10.1056/NEJMoa1703327
  15. Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airò P, et al. Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology 2020; 59: 1684-94. DOI: https://doi.org/10.1093/rheumatology/kez486
  16. Hemu M, Zimmerman A, Kalra D, Okwuosa T. Pretransplant cardiac evaluation using novel technology. J Clin Med 2019; 8: 690. DOI: https://doi.org/10.3390/jcm8050690
  17. Binks M. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-84. DOI: https://doi.org/10.1136/ard.60.6.577
  18. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506. DOI: https://doi.org/10.1016/S0140-6736(11)60982-3
  19. Van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-8. DOI: https://doi.org/10.1001/jama.2014.6368

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.